Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and COVID-19 treatments.
—————
Boost Internet Speed–
Free Business Hosting–
Free Email Account–
Dropcatch–
Free Secure Email–
Secure Email–
Cheap VOIP Calls–
Free Hosting–
Boost Inflight Wifi–
Premium Domains–
Free Domains